长春百克生物科技股份公司 关于持股 5%以上股东、董事、总经理自愿承诺 未来六个月内不减持公司股份的公告 长春百克生物科技股份公司（以下简称"公司"）于 2023 年 10 月 17 日收 到公司持股 5%以上股东、董事、总经理孔维先生出具的《关于未来六个月内不 减持公司股份的承诺函》，承诺内容具体如下： 证券代码：688276 证券简称：百克生物 公告编号：2023-039 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特此公告。 长春百克生物科技股份公司董事会 2023 年 10 月 18 日 基于对公司未来发展前景的信心及投资价值的认可，公司持股 5%以上股东、 董事、总经理孔维先生自愿承诺自本承诺函出具之日起的未来六个月内（即 2023 年 10 月 18 日至 2024 年 4 月 17 日期间）不以任何方式减持其所持有的公司全部 股份。在上述承诺期内如发生公司送红股、转增股本、配股等增加的股份亦遵守 上述承诺。 截至本公告披露日，孔维先生持有的公司股份数量为 104,448,497 股，占公 司总股本的比例为 ...

证券代码：688276 证券简称：百克生物 长春百克生物科技股份公司投资者关系活动记录表 编号：2023-011 特定对象调研 £分析师会议 £媒体采访 £业绩说明会 投资者关系活 £新闻发布会 £路演活动 动类别 £现场参观 £其他（请文字说明其他活动内容） 广发基金、国泰基金、高毅资产、高毅资产、富国基金、 参与单位名称 华安基金、长城基金唐、泓澄投资、中金资管、湘财基 及人员姓名 金、信达证券 时间 2023年9月20日10:00、15:00 ...

中信证券股份有限公司关于长春百克生物科技股份公司 2023年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为长春百克 生物科技股份公司（以下简称"百克生物"或"公司"）首次公开发行股票并在科创 板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》、《上海证券 交易所科创板股票上市规则》、《上海证券交易所科创板上市公司自律监管指引 第1号——规范运作》以及《科创板上市公司持续监管办法（试行）》、《上海 证券交易所上市公司自律监管指引第11号——持续督导》等相关规定，负责百克 生物上市后的持续督导工作，并出具本持续督导年度跟踪报告。 | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制 | 保荐机构已建立健全并有效执行了持续 | | 1 | 度，并针对具体的持续督导工作制定相 | 督导制度，并制定了相应的工作计划。 | | | 应的工作计划。 | | | | 根据中国证监会相关规定，在持续督导 | 保荐机构已与百克生物签订保荐协议， | | | 工作开始前，与上市公司签署持续督导 | | | 2 | ...

2023 年半年度报告 公司代码：688276 公司简称：百克生物 长春百克生物科技股份公司 2023 年半年度报告 1 / 176 2023 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险，敬请查阅本报告第三节 "管理层讨论与分析"中"风险因素"相关的内容。 三、公司全体董事出席董事会会议。 四、本半年度报告未经审计。 五、公司负责人马骥、主管会计工作负责人孟昭峰及会计机构负责人（会计主管人员）孟昭峰声 明：保证半年度报告中财务报告的真实、准确、完整。 六、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺，敬 请投资者注意投资风险。 九、是否存在被控股股东及其他关联方非经营性占用资金情况 否 十、是否存在 ...

2023 年第一季度报告 单位：元 币种：人民币 证券代码：688276 证券简称：百克生物 长春百克生物科技股份公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人马骥、主管会计工作负责人孟昭峰及会计机构负责人（会计主管人员）林爽保证季度 报告中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是√否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | |-----------------------------------------------|----------------|-----------------------------------|--------| | 项目 | 本报告期 | 本报告期比上年同期 增减变动幅度（ | % ） | | 营业收入 ...

Financial Performance - Revenue for 2022 was RMB 1,071,446,025.21, a decrease of 10.86% compared to 2021[16] - Net profit attributable to shareholders was RMB 181,536,723.75, down 25.46% year-over-year[16] - Operating cash flow decreased by 71.62% to RMB 39,818,408.14[16] - Total assets increased by 2.61% to RMB 4,283,551,750.23[16] - Shareholders' equity grew by 4.15% to RMB 3,559,536,200.04[16] - Basic earnings per share dropped by 29.03% to RMB 0.44[17] - Weighted average ROE decreased by 4.11 percentage points to 5.21%[17] - The decline in performance was mainly due to market demand fluctuations affecting product sales[17] - Basic earnings per share, diluted earnings per share, and basic earnings per share after deducting non-recurring gains and losses decreased by 29.03%, 29.03%, and 33.33% respectively, mainly due to the decline in net profit for the year[18] - Operating income for Q1, Q2, Q3, and Q4 were 137.8 million yuan, 303.12 million yuan, 424.8 million yuan, and 205.73 million yuan respectively[20] - Net profit attributable to shareholders of the listed company for Q1, Q2, Q3, and Q4 were 17.32 million yuan, 56.26 million yuan, 138.25 million yuan, and -30.28 million yuan respectively[20] - Non-recurring gains and losses for 2022 amounted to 14.78 million yuan, including government subsidies of 18.57 million yuan[21][22] - The company's total operating income for 2022 was 1.07 billion yuan, a decrease of 130.58 million yuan or 10.86% compared to the previous year[25] - Net profit attributable to shareholders of the parent company was 181.54 million yuan, a decrease of 62.02 million yuan or 25.46% compared to the previous year[25] - The company incurred a provision for inventory impairment of 60.17 million yuan for nasal spray influenza vaccines and 2.25 million yuan for contract performance costs, totaling 62.43 million yuan[26] - The company disposed of nasal spray devices and other raw materials nearing expiration, resulting in a loss of 23.36 million yuan[26] - Gross profit margin for the main business was 87.19%, a decrease of 1.11 percentage points year-over-year[68] - Sales of varicella vaccine were 7.77 million doses, a decrease of 4.27% year-over-year[71] - Sales of nasal spray influenza vaccine were 387,200 doses, a decrease of 35.85% year-over-year[71] - Total liabilities at the end of 2022 were RMB 724.02 million, a decrease of 4.36% compared to the beginning of the year[65] - R&D expenses were RMB 133.53 million, a decrease of 14.82% year-over-year[67] - Net cash flow from operating activities was RMB 39.82 million, a decrease of 71.62% year-over-year[67] - Net cash flow from financing activities was RMB -41.28 million, a decrease of 102.94% year-over-year[67] - Direct material costs decreased by 10.10% to 33,574,583.11 yuan, accounting for 24.47% of total costs[72] - Manufacturing expenses increased by 19.93% to 52,917,498.05 yuan, accounting for 38.57% of total costs[72] - Transportation and storage costs decreased by 23.87% to 30,519,110.90 yuan, accounting for 22.24% of total costs[72] - Total costs for varicella vaccine decreased by 1.61% to 28,598,491.55 yuan, accounting for 20.84% of total costs[73] - Manufacturing expenses for nasal spray flu vaccine increased by 58.75% to 12,758,366.18 yuan, accounting for 9.30% of total costs[73] - Management expenses increased by 33.29% to 144,471,039.87 yuan due to personnel and salary adjustments[80] - Cash flow from operating activities decreased by 71.62% to 39,818,408.14 yuan due to reduced sales collections[82] - Cash flow from financing activities decreased by 102.94% to -41,284,069.80 yuan due to the absence of fundraising activities compared to the previous year[84] - Prepayments increased by 50.63% to RMB 27,250,172.66, mainly due to increased prepaid R&D service fees[85] - Other receivables increased by 104.82% to RMB 2,907,554.92, primarily due to increased freight advances[85] - Long-term deferred expenses surged by 972.56% to RMB 32,637,941.06, mainly due to the transfer of validation costs for the relocation of the varicella packaging workshop[85] - Deferred tax assets increased by 69.74% to RMB 54,197,208.96, driven by increased deductible temporary differences from inventory impairment provisions[85] - Accounts payable decreased by 61.19% to RMB 24,802,342.50, mainly due to payments for procurement[85] - Taxes payable increased by 128.57% to RMB 9,845,002.13, primarily due to an increase in corporate income tax payable[85] - Other current liabilities rose by 101.09% to RMB 138,702,869.17, mainly due to increased expected returns of influenza vaccines[85] - Total investment for the reporting period was RMB 132,120,104.68, a 0.26% increase from the previous year[107] - The cumulative fair value change of financial assets measured at fair value was RMB -6,130,445.56[108] - The ending balance of other equity instrument investments was RMB 33,238,398.53[109] - Huikang Biotech, a wholly-owned subsidiary, reported a net loss of 40.7846 million yuan with zero revenue and negative net assets of 341.6478 million yuan[111] - Ruizhou Biotech, a 10% equity investment, reported a net loss of 48.2435 million yuan with revenue of 708,000 yuan and net assets of 119.6356 million yuan[111] - Ningbo Chunpai, a 33.62% equity investment, reported a net profit of 1.2369 million yuan with revenue of 12.3663 million yuan and net assets of 66.3968 million yuan[111] - The company's revenue for 2022 reached $96.77 billion, marking a significant milestone in its financial performance[133] - The company achieved a 15% year-over-year growth in user base, reaching 500 million active users globally[133] - The company's net profit margin improved by 5 percentage points to 25% in 2022, driven by cost optimization and operational efficiency[133] - The company launched three new products in 2022, contributing $500 million to its annual revenue[133] - The company provided a positive outlook for 2023, projecting a revenue growth of 10-15% and a net profit margin of 26-28%[133] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 1.50 yuan per 10 shares, totaling 61,926,104.70 yuan, which accounts for 34.11% of the net profit attributable to shareholders in 2022[3] - 2022 cash dividend proposal: RMB 1.50 per 10 shares, totaling RMB 61,926,104.70, accounting for 34.11% of the net profit attributable to shareholders[155][157] - 2021 cash dividend: RMB 1.00 per 10 shares, totaling RMB 41,284,069.80, accounting for 16.95% of the net profit attributable to shareholders[155] R&D and Innovation - R&D expenditure accounted for 14.54% of revenue, down 1.49 percentage points[17] - R&D investment reached 155.77 million yuan, accounting for 14.54% of revenue[27] - The company completed Phase I and II clinical trials for the liquid nasal spray influenza vaccine[27] - The company's shingles vaccine obtained the "Drug Registration Certificate"[27] - The company completed Phase I clinical trials for the DTaP vaccine (three-component) and is preparing for Phase III clinical samples[27] - The company's rabies monoclonal antibody entered the clinical trial stage[27] - The company has 13 vaccine projects and 2 monoclonal antibody projects in the pipeline, with key projects like DTaP vaccine, liquid nasal spray influenza vaccine, and rabies monoclonal antibody in clinical trials[31] - The company has established four core technology platforms: virus large-scale culture, formulation and adjuvant, genetic engineering, and bacterial vaccine technology platforms[38] - The virus large-scale culture technology platform has enabled the development and market approval of the varicella vaccine and the herpes zoster vaccine[39] - The formulation and adjuvant technology platform has led to the development of a 36-month shelf-life varicella vaccine and is advancing liquid formulations for nasal spray flu vaccines[40] - The genetic engineering technology platform is being used to develop vaccines and monoclonal antibodies for diseases such as Alzheimer's, rabies, and tetanus[41] - The company's bacterial vaccine technology platform includes large-scale bacterial fermentation, polysaccharide-protein conjugation, and purification techniques, with ongoing R&D for acellular pertussis-diphtheria-tetanus (three-component) combined vaccine and Haemophilus influenzae type b conjugate vaccine[42] - The company obtained 6 new invention patents during the reporting period, bringing the total number of invention patents to 42[43] - Total R&D investment in 2022 was RMB 155.77 million, a decrease of 19.16% year-over-year, with R&D investment accounting for 14.54% of operating revenue[45] - The company has 8 major R&D projects with cumulative investments exceeding RMB 500 million, including a pertussis-diphtheria-tetanus vaccine (RMB 100.09 million invested) and a zoster vaccine (RMB 181.97 million invested)[46] - The company has 132 R&D personnel, accounting for 10.54% of total employees, with an average annual salary of RMB 148,200[48] - The company has technical collaborations with Jilin University, Chinese Academy of Medical Sciences, and international partners like Intravacc[50] - The company's varicella vaccine maintains a leading market share, and the intranasal flu vaccine, the only approved live attenuated flu vaccine in China, was launched in the second half of 2020[51] - The company has a robust R&D pipeline with 13 vaccine candidates and 2 monoclonal antibodies for infectious disease prevention, including a pertussis-diphtheria-tetanus vaccine (three-component) leading in domestic development[51] - The company has completed Phase I and II clinical trials for its liquid intranasal flu vaccine, addressing stability issues and expanding the target population[51] - R&D investment in the reporting period was RMB 155.77 million, accounting for 14.54% of revenue[91] - The company obtained production approval for the herpes zoster vaccine in January 2023[91] - The liquid nasal spray influenza vaccine completed Phase I and II clinical trials[91] - R&D investment for the year reached RMB 75,388.88 thousand, accounting for 21.77% of revenue and 8.89% of net assets[98] - R&D expenditure for the bivalent pertussis vaccine (three-component) decreased by 38.95% to RMB 1,182.38 thousand[99] - R&D expenditure for the zoster vaccine decreased by 38.08% to RMB 2,224.33 thousand[99] - R&D expenditure for the influenza virus split vaccine (BK-01 adjuvant) increased by 110.72% to RMB 606.55 thousand[99] - R&D expenditure for the fully human anti-rabies virus monoclonal antibody decreased by 75.56% to RMB 1,507.64 thousand[99] - The company's R&D expenditure increased by 10% to $1.2 billion, focusing on AI and biotechnology innovations[133] Corporate Governance and Leadership - The company has no instances of non-operational fund occupation by controlling shareholders or related parties[4] - The company has no violations in decision-making procedures for external guarantees[5] - The company has no instances where more than half of the directors cannot guarantee the authenticity, accuracy, and completeness of the annual report[5] - The company's 2022 annual report has been audited by Da Xin Certified Public Accountants, who issued a standard unqualified audit report[3] - The company's 2022 annual report includes forward-looking statements regarding future plans and development strategies, which do not constitute a substantive commitment to investors[4] - The company's 2022 annual report includes a detailed list of major shareholders and shareholding changes[6] - The company's board of directors has established four specialized committees: Strategy Committee, Nomination Committee, Audit Committee, and Compensation and Evaluation Committee[121] - The company has appointed 3 independent directors to enhance the objectivity, scientificity, and fairness of board decisions[121] - The company's chairman, Ma Ji, holds 0 shares and received 0 RMB in pre-tax compensation during the reporting period[128] - Kong Wei, the company's director, general manager, and core technical personnel, holds 10,426.06 million shares and received 1.2144 million RMB in pre-tax compensation[128] - Jiang Chunlai, the company's director, executive vice president, and core technical personnel, increased his shareholding by 1.2399 million shares during the reporting period[128] - Feng Daqiang, the chairman of the supervisory board, increased his shareholding by 1.3318 million shares during the reporting period[128] - Wei Wei, the company's vice president and core technical personnel, increased her shareholding by 1.1022 million shares during the reporting period[128] - The company's independent directors each received 72,000 RMB in pre-tax compensation during the reporting period[128] - The company's financial director, Meng Zhaofeng, received 822,700 RMB in pre-tax compensation during the reporting period[128] - Total company shares held by key personnel amount to 10,453.76 million, with a total value of 11,096.70 million, resulting in a net increase of 642.94 million[130] - Key personnel, including Yu Bing, Liu Dawei, and Zhu Changlin, transitioned from indirect to direct shareholding due to the dissolution of Daohe Biotechnology[130] - Ma Ji serves as the Chairman and Party Secretary of Changchun High-Tech Industry (Group) Co., Ltd., with extensive experience in various leadership roles since 1986[131] - Jiang Yuntao is the current Director and General Manager of Changchun High-Tech Industry (Group) Co., Ltd., with a career spanning from 1997 to present[131] - Li Xiufeng holds the position of Vice President at Changchun High-Tech Industry (Group) Co., Ltd., with a background in various managerial roles since 2019[131] - Zhu Xinggong is the Vice President and CFO of Changchun High-Tech Industry (Group) Co., Ltd., with prior experience in financial roles at Jilin Huakang Pharmaceutical Co., Ltd.[131] - Company Chairman Ma Ji indirectly holds 21,900 shares of the company through Changchun High-Tech[136] - Director Jiang Yuntao indirectly holds 20,100 shares of the company through Changchun High-Tech[136] - Director Li Xiufeng indirectly holds 25,300 shares of the company through Changchun High-Tech[136] - Director Zhu Xinggong indirectly holds 25,100 shares of the company through Changchun High-Tech[136] - Supervisor Zhang Deshen indirectly holds 23,200 shares of the company through Changchun High-Tech[136] - Chairman Ma Ji serves as Chairman of Changchun High-Tech from June 23, 2021, to June 22, 2024[137] - Director Jiang Yuntao serves as Director and General Manager of Changchun High-Tech from June 23, 2021, to June 22, 2024[137] - Director Li Xiufeng serves as Vice President of Changchun High-Tech from June 23, 2021, to June 22, 2024[137] - Director Zhu Xinggong serves as Vice President and CFO of Changchun High-Tech from June 23, 2021, to June 22, 2024[137] - Supervisor Zhang Deshen serves as Board Secretary and Chief Legal Officer of Changchun High-Tech from June 23, 2021, to June 22, 2024[137] - Total compensation for directors, supervisors, and senior management at the end of the reporting period was RMB 6.7829 million[140] - Total compensation for core technical personnel at the end of the reporting period was RMB 5.0867 million[140] - The company's Board of Directors approved the 2021 annual financial report and the 2022 financial budget report during the fifth board meeting[142] - The company's Board of Directors approved the 2021 profit distribution plan during the fifth board meeting[142] - The company's Board of Directors approved the signing of a contract for the development of a recombinant zoster vaccine (CHO cell) during the fifth board meeting[142] - The company's Board of Directors approved the 2021 annual report and its summary during the fifth board meeting[142] - The company's Board of Directors approved the 2021 annual board work report during the fifth board meeting[142] - The company's Board of Directors approved the 2021 annual asset impairment provision during the fifth board meeting[142] - The company's Board of Directors approved the 2021 annual financial report during the fifth board meeting[142] - The company's Board of Directors approved the 2022 financial budget report during the fifth board meeting[142] - The company held a total of 10 board meetings in 2022, with 8 conducted via a combination of on-site and teleconference methods, and 2 via teleconference only[145] - The Audit Committee held 5 meetings in 2022, reviewing key reports including the 2021 Annual Report, 2022 Q1 Report, 202